News | July 11, 2012

Study Shows Safety of Ultrasound Contrast Agent

Study evaluated more than 1,000 patients with wide-ranging characteristics, including pre-existing cardiopulmonary conditions and critical illness

Study Shows Safety of Ultrasound Contrast Agent

July 11, 2012 — Lantheus Medical Imaging Inc., a developer, manufacturer and distributor of diagnostic imaging agents, announced the publication of results from the CaRES (Contrast Echocardiography Registry for Safety Surveillance) multicenter safety registry for its ultrasound imaging agent Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The CaRES study found that Definity was well-tolerated in patients of different types undergoing clinically-indicated Definity-enhanced echocardiography in a broad range of typical clinical settings. The results were published in the July 2012 issue of the Journal of the American Society of Echocardiography (Weiss et al, 2012)

The prospective, open-label, nonrandomized registry study was designed to assess the risk of adverse clinical events occurring within 30 minutes of Definity administration in a routine clinical setting. Among the 1,053 patients who completed the study, no deaths, life-threatening events, serious adverse events or serious anaphylactoid (allergic) reactions were reported during or after Definity administration. The overall adverse event (AE) rate was 10.8 percent, and drug-related AE rate was 3.5 percent. Of the AEs that occurred during or after Definity administration, a substantial majority 96.5 percent were mild to moderate in intensity.

The CaRES study complements another recently published study on the hemodynamic effects of Definity in patients with pulmonary hypertension. Published in the May 2012 issue of the Journal of the American Society of Echocardiography (Wei et al, 2012), this prospective study evaluated 32 patients, half of whom had elevated baseline pulmonary artery systolic pressures. The study found that Definity administration did not result in any clinically meaningful changes in systemic and pulmonary artery hemodynamic measurements among patients with either normal or elevated pulmonary artery pressure. In addition, no serious or fatal adverse events occurred. Overall, Definity demonstrated a positive safety profile and was well-tolerated.

Both the CaRES study and the pulmonary hypertension study were developed in conjunction with the U.S. Food and Drug Administration (FDA) in 2008 as part of a risk assessment program for perflutren-based ultrasound contrast agents such as Definity.  In October 2011, the FDA approved several revisions to the Definity prescribing information, including the removal of mandatory physiologic monitoring requirements for patients with pulmonary hypertension or unstable cardiopulmonary conditions.  Data from both the CaRES and pulmonary hypertension studies were included in the updated Definity labeling.

For more information: www.definityimaging.com

Related Content

Civco Medical Solutions Introduces Envision Viral Barrier at RSNA 2018
News | Ultrasound Imaging | November 20, 2018
Civco Medical Solutions will present Envision, the next generation of ultrasound probe covers and scan pads, at the...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
SuperSonic Imagine Introduces Aixplorer Mach 30 Ultrasound at The Liver Meeting
Technology | Ultrasound Imaging | November 14, 2018
SuperSonic Imagine recently exhibited at The Liver Meeting, held Nov. 9-13 in San Francisco, where the company...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
New Robotic Arm System Optimizes Testing of Ultrasound Probes

Image courtesy of Esaote

News | Ultrasound Imaging | November 09, 2018
Medical imaging company Esaote and The BioRobotics Institute of Scuola Superiore Sant’Anna in Pisa, Italy, have...
The Acuson Sequoia

The Acuson Sequoia from Siemens Healthineers.

Feature | Ultrasound Imaging | November 05, 2018 | By Jeff Zagoudis
As the world’s most utilized medical imaging modality, ultrasound is likely to be featured heavily at the 2018...
Fujifilm SonoSite Launches New Point-of-Care Ultrasound Educational Resources
News | Ultrasound Imaging | November 01, 2018
Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational...
Vygon and Sonoscanner Partnering on New Ultrasound System for Catheter Placement Guidance
News | Cardiovascular Ultrasound | October 31, 2018
Vygon, an international group specialized in single-use medical devices, and French company Sonoscanner announced the...
Cardiac Ultrasound Software Streamlines Fetal Heart Exams
Feature | Cardiovascular Ultrasound | October 30, 2018
A new tool called fetalHQ on GE Healthcare’s Voluson ultrasound systems is the first tool to simultaneously examine the...